DFCI 11-237: A Feasibility trial of Everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic Leukemia (ALL)

      Project: Research project

      Project Details

      StatusFinished
      Effective start/end date11/1/1310/31/18

      Funding

      • Dana-Farber Cancer Institute
      • Novartis Pharmaceuticals Corporation